{"id":32598,"date":"2021-06-02T07:00:00","date_gmt":"2021-06-02T00:00:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021060207000032598"},"modified":"2021-06-02T21:40:11","modified_gmt":"2021-06-02T13:40:11","slug":"%e5%be%b7%e7%90%aa%e5%8c%bb%e8%8d%af%e5%a1%9e%e5%88%a9%e5%b0%bc%e7%b4%a212%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%91%98%e8%a6%81%e5%85%a5%e9%80%892021-eha%e5%b9%b4%e4%bc%9a","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021060207000032598","title":{"rendered":"\u5fb7\u742a\u533b\u836f\u585e\u5229\u5c3c\u7d2212\u9879\u7814\u7a76\u6458\u8981\u5165\u90092021 EHA\u5e74\u4f1a"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/www.xinwengao.com\/cn\/wp-content\/uploads\/ANTENGENE_Logo-3.jpg\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p><span id=\"spanHghlt72e5\">\u4e0a\u6d77\u548c\u9999\u6e2f<\/span>2021\u5e746\u67082\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;&nbsp;\u81f4\u529b\u4e8e\u7814\u53d1\u548c\u5546\u4e1a\u5316\u521b\u65b0\u80bf\u7624\u7597\u6cd5\u7684\u9886\u5148\u751f\u7269\u5236\u836f\u516c\u53f8&#8211;\u5fb7\u742a\u533b\u836f\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u5fb7\u742a\u533b\u836f\u201d\uff0c\u9999\u6e2f\u8054\u4ea4\u6240\u80a1\u7968\u4ee3\u7801\uff1a6996.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u540c\u7c7b\u9996\u6b3e\u9009\u62e9\u6027\u6838\u8f93\u51fa\u6291\u5236\u5242\u2014\u2014\u585e\u5229\u5c3c\u7d22\uff08selinexor\uff0912\u9879\u7814\u7a76\u53ca\u6210\u679c\u5165\u9009\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u3002\u6b64\u5c4a EHA \u4f1a\u8bae\u5c06\u4e8e6\u67089\u65e5\u81f36\u670817\u65e5\u5728\u7ebf\u4e0a\u53ec\u5f00\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder7254\">\n<\/p><\/div>\n<p><span id=\"spanHghltf699\"><\/span><\/p>\n<p><b>\u7ebf\u4e0a\u6458\u8981<\/b><\/p>\n<p>Phase 2 MARCH study of oral ATG-010 plus low dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously exposed to an immunomodulatory agent and a proteasome inhibitor.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aPB1670<\/p>\n<p>Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aS188<\/p>\n<p>Selinexor containing regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP1002<\/p>\n<p>Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed\/refractory multiple myeloma (MM).<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP1008<\/p>\n<p>Ciltacabtagene Autoleucel versus selinexor + dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM) treated with \u2265 3 lines of prior therapy\uff1aA matching adjusted indirect comparison.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP1049<\/p>\n<p>Cost effectiveness comparison of belantamab mafodotin and selinexor in relapsed refractory multiple myeloma.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP1173<\/p>\n<p>Lymphocyte count effect on efficacy and safety of single agent oral selinexor in patients with relapsed\/refractory diffuse large B-cell lymphoma\uff08DLBCL\uff09\uff1aA post-hoc analysis from phase <span class=\"xn-money\">2B<\/span> SADAL study.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP530<\/p>\n<p>Genomic correlates of respones to selinexor in multiple myeloma from the <span class=\"xn-location\">BOSTON<\/span> study reveal a predictive signature.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP936<\/p>\n<p>Effects of selinexor on previously treated multiple myeloma (MM) with RAS-mutations.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP966<\/p>\n<p>Efficacy and safety of selinexor, bortezomib, and dexamethasone based on refractory status to lenalidomide in patients with previously treated multiple myeloma\uff1aA post-hoc analysis of the <span class=\"xn-location\">BOSTON<\/span> study.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP974<\/p>\n<p>Survival among older patients with previously treated multiple myeloma treated with selinexor\uff0cbortezomib, and dexamethasone (XVd) in the <span class=\"xn-location\">BOSTON<\/span> study.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP976<\/p>\n<p>Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEP924<\/p>\n<p>\u5173\u4e8e\u5fb7\u742a\u533b\u836f<\/p>\n<p>\u5fb7\u742a\u533b\u836f\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u5fb7\u742a\u533b\u836f\u201d\uff0c\u9999\u6e2f\u8054\u4ea4\u6240\u80a1\u7968\u4ee3\u7801\uff1a6996.HK\uff09\u662f\u4e00\u5bb6\u4ee5\u7814\u53d1\u4e3a\u9a71\u52a8\u7684\u751f\u7269\u5236\u836f\u9886\u5148\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u4e3a\u4e9a\u592a\u4e43\u81f3\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u6700\u9886\u5148\u7684\u7597\u6cd5\uff0c\u6cbb\u7597\u80bf\u7624\u53ca\u5176\u4ed6\u5371\u53ca\u751f\u547d\u7684\u75be\u75c5\u3002\u81ea2017\u5e74\u6b63\u5f0f\u8fd0\u8425\u4ee5\u6765\uff0c\u5fb7\u742a\u533b\u836f\u901a\u8fc7\u5408\u4f5c\u5f15\u8fdb\u548c\u81ea\u4e3b\u7814\u53d1\uff0c\u5efa\u7acb\u4e86\u4e00\u6761\u4ece\u4e34\u5e8a\u524d\u5230\u4e34\u5e8a\u9636\u6bb5\u4e0d\u65ad\u5ef6\u5c55\u7684\u4e30\u5bcc\u4ea7\u54c1\u7ba1\u7ebf\u3002\u76ee\u524d\uff0c\u5fb7\u742a\u533b\u836f\u5df2\u5728\u591a\u4e2a\u4e9a\u592a\u5e02\u573a\u83b7\u5f9715\u4e2a\u4e34\u5e8a\u6279\u4ef6\uff08IND\uff09\uff0c\u5e76\u9012\u4ea4\u4e865\u4e2a\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff08NDA\uff09\u3002\u5fb7\u742a\u533b\u836f\u5c06\u4ee5\u201c\u533b\u8005\u65e0\u7586\uff0c\u521b\u65b0\u6c38\u7eed\u201d\u4e3a\u613f\u666f\uff0c\u4e13\u6ce8\u4e8e\u540c\u7c7b\u9996\u6b3e\u548c\u540c\u7c7b\u6700\u4f18\u7597\u6cd5\u7684\u65e9\u671f\u7814\u53d1\u3001\u4e34\u5e8a\u7814\u7a76\u3001\u836f\u7269\u751f\u4ea7\u53ca\u5546\u4e1a\u5316\uff0c\u89e3\u51b3\u4e9f\u5f85\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\">  <\/div>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<p>http:\/\/www.antengene.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e0a\u6d77\u548c\u9999\u6e2f2021\u5e746\u67082\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;&nbsp;\u81f4\u529b\u4e8e\u7814\u53d1\u548c\u5546\u4e1a\u5316\u521b\u65b0\u80bf\u7624\u7597\u6cd5\u7684\u9886\u5148\u751f\u7269\u5236\u836f\u516c\u53f8&#8211;\u5fb7\u742a\u533b\u836f\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u5fb7\u742a\u533b\u836f\u201d\uff0c\u9999\u6e2f\u8054\u4ea4\u6240\u80a1\u7968\u4ee3\u7801\uff1a6996.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u540c\u7c7b\u9996\u6b3e\u9009\u62e9\u6027\u6838\u8f93\u51fa\u6291\u5236\u5242\u2014\u2014\u585e\u5229\u5c3c\u7d22\uff08selinexor\uff0912\u9879\u7814\u7a76\u53ca\u6210\u679c\u5165\u9009\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u3002\u6b64\u5c4a EHA \u4f1a\u8bae\u5c06\u4e8e6\u67089\u65e5\u81f36\u670817\u65e5\u5728\u7ebf\u4e0a\u53ec\u5f00\u3002 \u7ebf\u4e0a\u6458\u8981 Phase 2 MARCH study of oral ATG-010 plus low dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously exposed to an immunomodulatory agent and a proteasome inhibitor. \u6458\u8981\u7f16\u53f7\uff1aPB1670 Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients. \u6458\u8981\u7f16\u53f7\uff1aS188 Selinexor containing regimens in patients&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021060207000032598\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":32601,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-32598","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=32598"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32598\/revisions"}],"predecessor-version":[{"id":32600,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32598\/revisions\/32600"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/32601"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=32598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=32598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=32598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}